Headache and Migraine

The director of the Hartford Healthcare Headache Center in Connecticut and lead investigator on the trial provided some insight into the study's findings.

As the scientific grasp of it gets tighter, ensuring physicians have an understanding of the diagnosis of and treatment options for cluster headache becomes of utmost importance.

Theranica, its developer, noted that it has completed regulatory submission for the device to the FDA, and that if approved, it plans to commercialize the product by the end of 2019.

While studies support the use of cannabis for pain in adults, a lack of clinical data and an inability to perform studies has slowed the medical community’s understanding of the drug’s conceivable use in headache conditions.

Eli Lilly intends to submit a supplemental biologics license application to the FDA for galcanezumab for the preventive treatment of episodic cluster headache by the end of 2018.

This case series appears to identify a new subtype of chronic daily headache in overweight/obese women in their fifties and sixties.

If approved, lasmiditan could represent the first significant innovation for acute treatment of migraine in more than 2 decades.

Recent work demonstrates that the anterior part of the hypothalamus is enlarged in cluster headache.

Your new patient is a 16-year-old high school student who received a diagnosis of chronic migraine two years ago. She has recently become sexually active. How would you counsel this patient?

The Global Medical Lead for Migraine and Headache at Teva Pharmaceuticals provided insight into how fremanezumab has helped to improve these facets of the condition.

Could 20 years of treatment for migraine have prompted a spontaneous absence of speech after this patient stopped taking her medication?

Neurology News Network for the week of November 3, 2018.

The president of the American Headache Society shared her thoughts on how preventive medicines can alter migraine treatment for the better.

Striking findings are a call for public policy and research initiatives for aging populations with neurologic conditions.

The study found that there has been a significant increasing trend in patients with migraine—irrespective of aura status—having an ischemic stroke.

Despite the explosion of preventive medications for migraine, a large need for acute care remains.

With many advancements in treatments occurring in recent years, the president of the American Headache Society urged for further research to continue to light the way.

Allergan is planning a 2019 NDA submission to the FDA for its agent, ubrogepant, based on a pair of new trials.

Symptoms of sudden onset of headache and decreased balance three days earlier prompted a visit to the emergency department.

The director of the Center of Neurogenetics at Weill Cornell Medicine spoke about the wealth of improvements that have really turned this area of medicine into a much more hopeful one.

The CGRP inhibitors are poised to transform the treatment paradigm for patients with migraine and cluster headache.

The Global Medical Lead for Migraine and Headache at Teva Pharmaceuticals, the therapy’s developer, discussed its performance in patients with medication overuse headache.

Cannabinoids are being explored in a variety of conditions, ranging from Alzheimer disease to migraine.

Physicians offer perspectives on newly approved products to prevent migraine.

What differentiates migraine from underlying intracranial pathology that may require neuroimaging, like tumors, abscesses, aneurysms, or hemorrhages? Test your skills with this 5-question quiz.